Letairis and Cellulitis - a phase IV clinical study of FDA data

Summary:

Cellulitis is reported as a side effect among people who take Letairis (ambrisentan), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Adcirca, and have Cor pulmonale chronic.

The phase IV clinical study analyzes which people have Cellulitis when taking Letairis. It is created by eHealthMe based on reports of 93,991 people who have side effects when taking Letairis from the FDA, and is updated regularly.

What is Letairis?

Letairis has active ingredients of ambrisentan. It is often used in pulmonary hypertension. eHealthMe is studying from 94,041 Letairis users. Check the latest studies of Letairis.

What is Cellulitis?

Cellulitis (infection under the skin) is found to be associated with 2,078 drugs and 2,341 conditions by eHealthMe. Check the latest studies of Cellulitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

93,991 people reported to have side effects when taking Letairis.
Among them, 412 people (0.44%) have Cellulitis.

Among these 412 people:

* Approximation only. Some reports may have incomplete information.

Do you take Letairis and have Cellulitis?

- Check whether Cellulitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Letairis:

Letairis (94,041 reports)

Cellulitis treatments and more:

Cellulitis (75,291 reports)

How severe was Cellulitis and when was it recovered:

Cellulitis in Letairis

Expand to all the drugs that have ingredients of ambrisentan:

Cellulitis and drugs with ingredients of ambrisentan

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Letairis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cellulitis:

Cellulitis (2,078 drugs)

Browse all the conditions that are associated with Cellulitis:

Cellulitis (2,341 conditions)

Related publications that referenced our studies

Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .
Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on ambrisentan (the active ingredients of Letairis) and Letairis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.